Commission Directive 2006/132/EC of 11 December 2006 amending Council Directive 91/414/EEC to include procymidone as active substance (Text with EEA relevance) (repealed)

COMMISSION DIRECTIVE 2006/132/EC

of 11 December 2006

amending Council Directive 91/414/EEC to include procymidone as active substance

(Text with EEA relevance) (repealed)

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to Council Directive 91/414/EEC of 15 July 1991 concerning the placing of plant protection products on the market⁽¹⁾, and in particular Article 6(1) thereof,

Whereas:

- (1) Commission Regulation (EEC) No 3600/92 of 11 December 1992 laying down the detailed rules for the implementation of the first stage of the programme of work referred to in Article 8(2) of Council Directive 91/414/EEC concerning the placing of plant protection products on the market⁽²⁾ establishes a list of active substances to be assessed, with a view to their possible inclusion in Annex I to Directive 91/414/EEC. That list includes procymidone.
- (2) For procymidone the effects on human health and the environment have been assessed in accordance with the provisions laid down in Regulation (EEC) No 3600/92 for a range of uses proposed by the notifier. By Commission Regulation (EC) No 933/94 of 27 April 1994 laying down the active substances of plant protection products and designating the Rapporteur Member State for the implementation of Commission Regulation (EEC) No 3600/92⁽³⁾, France was designated as Rapporteur Member State. France submitted the relevant assessment report and recommendations to the Commission on 15 January 2001 in accordance with Article 7(1)(c) of Regulation (EEC) No 3600/92.
- (3) The assessment report has been reviewed by the Member States and the Commission within the Standing Committee on the Food Chain and Animal Health.
- (4) It has appeared from the various examinations made that plant protection products containing procymidone may be expected to satisfy the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, with regard to the uses which were examined and detailed in the Commission review report, provided that adequate risk mitigation measures are applied. As procymidone is a hazardous substance, its use should not be unrestricted. In particular there are concerns about its intrinsic toxic effects, including potential endocrine disrupting properties. There is at present no scientific consensus on the exact extent of the risk. Applying the precautionary

- principle, and taking into account the current state of scientific knowledge, risk mitigation measures should be imposed in order to achieve the high level of protection of human and animal health and the environment chosen in the Community.
- (5) Articles 5(4) and 6(1) of Directive 91/414/EEC provide that inclusion of a substance in Annex I may be subject to restrictions and conditions. In this case, restrictions on the inclusion period and on the authorised crops are deemed necessary. The original measures presented to the Standing Committee on the Food Chain and Animal Health, proposed the restriction of the inclusion period to seven years, so that Member States would give priority to reviewing plant protection products already on the market containing procymidone. In order to avoid discrepancies in the high level of protection sought, the inclusion in Annex I to Directive 91/414/EEC was intended to be limited to the uses of procymidone that have been actually assessed within the Community evaluation and for which the proposed uses were considered to comply with the conditions of Directive 91/414/EEC. This implies that other uses, which were not or only partially covered by this assessment, had first to be subject to a complete assessment, before their inclusion in Annex I of Directive 91/414/EEC could be considered. Finally, due to the hazardous nature of procymidone, it was considered necessary to provide for a minimum harmonisation at Community level of certain risk mitigation measures that were to be applied by Member States when granting authorisations.
- (6) Under the procedures laid down by Directive 91/414/EEC, the approval of active substances, including the definition of risk management measures, is decided by the Commission. Member States bear the responsibility for the implementation, application and control of the measures intended to mitigate the risks generated by plant protection products. Concerns expressed by several Member States reflect their judgment that additional restrictions are necessary to reduce the risk to a level that can be considered acceptable and consistent with the high level of protection that is sought within the Community. At present, it is a question of risk management to set the adequate level of safety and protection for the continued production, commercialisation and use of procymidone.
- (7) As a consequence of the above, the Commission re-examined its position. In order to correctly reflect the high level of protection of human and animal health and a sustainable environment sought in the Community, it considered appropriate, in addition to the principles set out in recital 5, to further reduce the period of inclusion to 18 months instead of seven years. This further reduces any risk by ensuring a priority re-assessment of this substance.
- (8) It may be expected that plant protection products containing procymidone satisfy the requirements laid down in Article 5(1)(a) and (b) of Directive 91/414/EEC, with regard to the uses which were examined and detailed in the Commission review report and providing that the necessary risk mitigation measures are applied.
- (9) Without prejudice to the conclusion that plant protection products containing procymidone may be expected to satisfy the requirements laid down in Article 5(1) (a) and (b) of Directive 91/414/EEC, it is appropriate to obtain further information on

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

certain specific points. The potential endocrine-disrupting properties of procymidone have been assessed in test which follow the best currently available practice. The Commission is aware that the Organisation for Economic Cooperation and Development (OECD) is developing test guidelines in order to further refine the assessment of potential endocrine disrupting properties. Therefore it is appropriate to require that procymidone should be subjected to such further testing as soon as agreed OECD test guidelines exist and that such studies should be presented by the notifier. In addition, Member States should require authorisation holders to provide information on the use of procymidone including any information on incidences on operator health.

- (10) As with all substances included in Annex I to Directive 91/414/EEC, the status of procymidone could be reviewed pursuant to Article 5(5) of that Directive in the light of any new data becoming available. Equally, the fact that the inclusion of this substance in Annex I expires on a particular date does not prevent the inclusion being renewed according to the procedures laid down in the Directive.
- (11) The experience gained from previous inclusions in Annex I to Directive 91/414/EEC of active substances assessed in the framework of Regulation (EEC) No 3600/92 has shown that difficulties can arise in interpreting the duties of holders of existing authorisations in relation to access to data. In order to avoid further difficulties it therefore appears necessary to clarify the duties of the Member States, especially the duty to verify that the holder of an authorisation demonstrates access to a dossier satisfying the requirements of Annex II to that Directive. However, this clarification does not impose any new obligations on Member States or holders of authorisations compared to the directives which have been adopted until now amending Annex I.
- (12) A reasonable period should be allowed to elapse before an active substance is included in Annex I in order to permit Member States and the interested parties to prepare themselves to meet the new requirements which will result from the inclusion.
- (13) Without prejudice to the obligations defined by Directive 91/414/EEC as a consequence of including an active substance in Annex I, Member States should be allowed a period of six months after inclusion to review existing authorisations of plant protection products containing procymidone to ensure that the requirements laid down by Directive 91/414/EEC, in particular in its Article 13 and the relevant conditions set out in Annex I, are satisfied. Member States should vary, replace or withdraw, as appropriate, existing authorisations. in accordance with the provisions of Directive 91/414/EEC. By derogation from the above deadline, a longer period should be provided for the submission and assessment of the complete Annex III dossier of each plant protection product for each intended use in accordance with the uniform principles laid down in Directive 91/414/EEC. Given the hazardous properties of procymidone, the period for Member States to verify whether plant protection products containing procymidone, alone or in combination with other authorised active substances, comply with the provisions of Annex VI should not exceed 18 months.
- (14) It is therefore appropriate to amend Directive 91/414/EEC accordingly.
- (15) The Standing Committee on the Food Chain and Animal Health did not deliver an opinion within the time limit laid down by its Chairman and the Commission therefore

submitted to the Council a proposal relating to these measures. On the expiry of the period laid down in the second subparagraph of Article 19(2) of Directive 91/414/ EEC, the Council had neither adopted the proposed implementing act nor indicated its opposition to the proposal for implementing measures and it is accordingly for the Commission to adopt these measures,

HAS ADOPTED THIS DIRECTIVE:

Article 1 U.K.

Annex I to Directive 91/414/EEC is amended as set out in the Annex to this Directive.

Article 2 U.K.

Member States shall adopt and publish by 30 June 2007 at the latest the laws, regulations and administrative provisions necessary to comply with this Directive. They shall forthwith communicate to the Commission the text of those provisions and a correlation table between those provisions and this Directive.

They shall apply those provisions from 1 July 2007.

When Member States adopt those provisions, they shall contain a reference to this Directive or be accompanied by such a reference on the occasion of their official publication. Member States shall determine how such reference is to be made.

Article 3 U.K.

- 1 Member States shall in accordance with Directive 91/414/EEC, where necessary, amend or withdraw existing authorisations for plant protection products containing procymidone as an active substance by 30 June 2007. By that date they shall in particular verify that the conditions in Annex I to that Directive relating to procymidone are met, with the exception of those identified in part B of the entry concerning that active substance, and that the holder of the authorisation has, or has access to, a dossier satisfying the requirements of Annex II to that Directive in accordance with the conditions of Article 13.
- By derogation from paragraph 1, for each authorised plant protection product containing procymidone, Member States shall re-evaluate the product in accordance with the uniform principles provided for in Annex VI to Directive 91/414/EEC, on the basis of a dossier satisfying the requirements of Annex III to that Directive and taking into account part B of the entry in Annex I to that Directive concerning procymidone. On the basis of that evaluation, they shall determine whether the product satisfies the conditions set out in Article 4(1)(b), (c), (d) and (e) of Directive 91/414/EEC.

Following that determination Member States shall for products containing procymidone, where necessary, amend or withdraw the authorisation by 30 June 2008.

Article 4 U.K.

This Directive shall enter into force on 1 January 2007.

Article 5 U.K.

This Directive is addressed to the Member States.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

ANNEX U.K.

The following entries shall be added at the end of the table in Annex I to Directive 91/414/EEC:

No	Common name, identification numbers	IUPAC name on	Purity ^a	Entry into force	Expiration of inclusion	Specific provisions
`146	Procymidono CAS No 32809-16-8 CIPAC No 383	dichloropher	lopropane-1,2	1 January 2007	30 June 2008	PART A Only uses as fungicide on the following crops may be authorised: — cucumbers in greenhouses (closed hydroponic systems), plums (for processing) at rates not exceeding — [F10,75 kg active substance per hectare per application. The following uses must not be authorised: — air application, — knapsack and hand- held applications neither

a Further details on identity and specification of active substance are provided in the review report.

			by amateur nor by professional users, home gardening. Member States shall ensure that all appropriate risk mitigation measures are applied. Particular attention must be paid to the protection of: — aquatic organisms. Where relevant, an appropriate distance must be kept between treated areas and surface water bodies. This distance may
			and surface water bodies. This distance

 $^{{\}bf a} \qquad \text{Further details on identity and specification of active substance are provided in the review report.}$

techniques or devices, birds and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of the				
or devices, birds and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				techniques
devices, birds and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of of the exposure				
birds and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
and mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				uevices,
mammals. Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
Conditions of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of of				
of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				mammals.
of authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				Conditions
authorisation shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				of
shall include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of of				
include risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
risk mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
mitigation measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
measures, such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				mitigation
such as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
as a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				such
a judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of of				
judicious timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of of				
timing of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
of the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				Judicious
the application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				timing
application and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				the
and the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				application
the selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				and
selection of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
of those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
those formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
formulations which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
which, as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
as a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
a result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
result of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				as
of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				a
of their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				result
their physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
physical presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				
presentation or the presence of agents that ensure an adequate avoidance, minimise the exposure of				nhysical
or the presence of agents that ensure an adequate avoidance, minimise the exposure of				progentation
the presence of agents that ensure an adequate avoidance, minimise the exposure of				~
presence of agents that ensure an adequate avoidance, minimise the exposure of				
of agents that ensure an adequate avoidance, minimise the exposure of				
agents that ensure an adequate avoidance, minimise the exposure of				presence
that ensure an adequate avoidance, minimise the exposure of				
that ensure an adequate avoidance, minimise the exposure of				agents
ensure an adequate avoidance, minimise the exposure of				that
an adequate avoidance, minimise the exposure of				
adequate avoidance, minimise the exposure of				
avoidance, minimise the exposure of				
minimise the exposure of				avoidance
the exposure of				avoidance,
exposure of				minimise
of				
of the				exposure
the				of
				the

a Further details on identity and specification of active substance are provided in the review report.

				concerned
				species,
				consumers,
				the
				acute
				dietary
				exposure
				of
				which
				must
				be
				controlled,
			_	groundwater,
				when
				the
				active
				substance
				is
				applied
				in
				regions
				with
				vulnerable
				soil
				and/
				or
				climatic
				conditions.
				Conditions
				of
				authorisation
				shall
				include
				risk
				mitigation
				measures,
			_	operators,
				who
				must
				wear
				suitable
				protective
				clothing,
				in
				particular
				gloves,
				coveralls,
				rubber
				boots
				and
				face
				protection

 $^{{\}bf a} \qquad \text{Further details on identity and specification of active substance are provided in the review report.}$

				or
				safety
				glasses
				during
				mixing,
				loading,
				application
				and
				cleaning
				of
				equipment,
				unless
				the
				exposure
				to
				the
				substance
				is
				adequately
				precluded
				by
				the
				design
				and
				construction
				of
				the
				equipment
				itself
				or
				by
				the
				mounting
				of
				specific
				protective
				components
				on
				such
				equipment,
				workers, who
				must
				wear
				suitable
				protective
				clothing,
				in
				particular
				gloves
				gloves, if
				they
 ., .,	 	 		

a Further details on identity and specification of active substance are provided in the review report.

			must
			enter
			a
			treated
			area
			before
			the
			specific
			re-
			entry
			period has
			expired.
			PART B For
			the
			implementation
			of
			the uniform
			principles
			of
			Annex
			VI,
			the
			conclusions
			of
			the
			review
			report
			on
			procymidone,
			and
			in particular
			Appendices
			I
			and
			II
			thereof,
			shall
			be
			taken
			into
			account.
			Member
			States must
			ensure that the
			authorisation
			holders
			report at
			1

Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

the latest on 31 December of each year on incidences of operator health problems. Member States may require that elements, such as sales data and a survey of use patterns, are provided so that a realistic picture of the use conditions and the possible toxicological impact of procymidone can be obtained. Member States shall request the submission of further confirmatory data and information to prove the acceptability of the active substance when applied in situations where there is a likelihood

a Further details on identity and specification of active substance are provided in the review report.

of long
term
exposure
of wild
mammals,
and on the
sewage
treatment
applied in
the case of
greenhouse
applications.
Member
States shall
request the
submission
of further
studies to
address the
potential
endocrine
disrupting
properties
of
procymidone
within
two years
after the
adoption
of the Test
Guidelines
on
endocrine
disruption
by the
Organisation
for
Economic
Cooperation
and
Development
(OECD).
They shall
ensure that
the notifier
at whose
request
procymidone
has been
included in
this Annex
provide

a Further details on identity and specification of active substance are provided in the review report.

Status: EU Directives are being published on this site to aid cross referencing from UK legislation. After IP completion day (31 December 2020 11pm) no further amendments will be applied to this version.

ĺ	I		such
			studies
			to the
			Commission
			within two
			years of the
			adoption
			of the
			above test
			guidelines.'

a Further details on identity and specification of active substance are provided in the review report.

Textual Amendments

F1 Substituted by Commission Decision of 29 June 2007 correcting Directive 2006/132/EC amending Council Directive 91/414/EEC to include procymidone as active substance (notified under document number C(2007) 3066) (Text with EEA relevance) (2007/452/EC).

- (1) OJ L 230, 19.8.1991, p. 1. Directive as last amended by Commission Directive 2006/85/EC (OJ L 293, 24.10.2006, p. 3).
- (2) OJ L 366, 15.12.1992, p. 10. Regulation as last amended by Regulation (EC) No 2266/2000 (OJ L 259, 13.10.2000, p. 10).
- (3) OJ L 107, 28.4.1994, p. 8. Regulation as last amended by Regulation (EC) No 2230/95 (OJ L 225, 22.9.1995, p. 1).